Serum levels of vascular endothelial growth factor and cancer antigen 125 are related to the prognosis of adenomyosis patients after interventional therapy.

AIMS This study is to investigate the expression levels of vascular endothelial growth factor (VEGF) and cancer antigen 125 (CA125) in serum of adenomyosis patients before and after interventional therapy. The role of serum levels of VEGF and CA125 for the prognosis of adenomyosis is further studied. METHODS A total of 80 adenomyosis patients treated with interventional therapy and 40 healthy individuals were enrolled in this study. Enzyme-linked immunosorbent assay was performed to detect the expression levels of VEGF and CA125. Receiver operating characteristic analysis was used to determine the treatment effect on adenomyosis. Kaplan-Meier analysis was used to analysis the progression-free survival curve for prognosis of adenomyosis. RESULTS The expression levels of VEGF and CA125 in serum of patients with adenomyosis was increased when compared with those of healthy individuals before interventional therapy (P < 0.05). Levels of hemoglobin in adenomyosis patients after surgery was increased compared with those before surgery (P < 0.05). The blood volume of menstruation, pain intensity, and volume of uterus in adenomyosis patients after surgery was significantly decreased when compared with those before surgery (P < 0.01). The survival rate of adenomyosis patients with high VEGF and CA125 levels was decreased. Serum levels of VEGF and CA125 had a high sensitivity and specificity for the prognosis of adenomyosis. CONCLUSIONS The serum expression levels of VEGF and CA125 are related to the development of adenomyosis. VEGF and CA125 serum levels can be used for predicting the prognosis of adenomyosis.